Skip to main content
. 2020 Sep 23;218(1):e20201214. doi: 10.1084/jem.20201214

Figure 1.

Figure 1.

Establishment of controller status following a 2-wk course of combination bNAb therapy beginning on PI day 3 in rhesus macaques inoculated with SHIVAD8-EO. (A–F) Plasma virus loads in six controller bNAb recipients over a 250–315-wk observation period are shown. Red arrows in each panel indicate the time of the anti-CD8α–depleting mAb MT807R1 infusion. Blue arrows for macaques MVJ, DEMR, and DEWL denote infusion of the anti-CD8β–depleting mAb CD8b255R1. The vertical dotted lines separate the previously reported results (Nishimura et al., 2017) from new data collected during the past 2.5–3.5 yr. IR, intrarectally; IV, intravenously.